Medios (ILM1) Stock Overview
Supplies specialty pharmaceutical drugs primarily in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ILM1 from our risk checks.
ILM1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medios AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €11.14 |
| 52 Week High | €17.44 |
| 52 Week Low | €10.80 |
| Beta | 1.29 |
| 1 Month Change | -10.31% |
| 3 Month Change | -20.66% |
| 1 Year Change | -14.96% |
| 3 Year Change | -34.00% |
| 5 Year Change | -68.66% |
| Change since IPO | 42.84% |
Recent News & Updates
Narrative Update • Jun 17
ILM1: Reaffirmed 2026 Guidance And CFO Transition Will Drive Future Upside
Analysts have maintained their €26.00 price target for Medios stock, citing slightly adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E that collectively support the current valuation framework. What’s in the News for Medios Medios AG confirmed earnings guidance for 2026, with expected revenue in a range of €2.0b to €2.12b.Narrative Update • Jun 03
ILM1: Reaffirmed 2026 Guidance And CFO Transition Will Support Future Upside
Analysts have kept their Medios price target steady at €26.0, citing updated assumptions around a slightly higher discount rate, a lower revenue growth outlook, a modestly higher profit margin, and a marginally lower future P/E multiple. What's in the News Medios AG confirmed earnings guidance for 2026, with expected revenue in a range of €2.0b to €2.12b.Recent updates
Narrative Update • Jun 17
ILM1: Reaffirmed 2026 Guidance And CFO Transition Will Drive Future Upside
Analysts have maintained their €26.00 price target for Medios stock, citing slightly adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E that collectively support the current valuation framework. What’s in the News for Medios Medios AG confirmed earnings guidance for 2026, with expected revenue in a range of €2.0b to €2.12b.Narrative Update • Jun 03
ILM1: Reaffirmed 2026 Guidance And CFO Transition Will Support Future Upside
Analysts have kept their Medios price target steady at €26.0, citing updated assumptions around a slightly higher discount rate, a lower revenue growth outlook, a modestly higher profit margin, and a marginally lower future P/E multiple. What's in the News Medios AG confirmed earnings guidance for 2026, with expected revenue in a range of €2.0b to €2.12b.Narrative Update • Apr 21
ILM1: CFO Transition And Revenue Outlook Will Support Future Upside Potential
Narrative Update on Medios Analysts keep their Medios price target steady at €26.00. They point to slightly firmer revenue growth, a modestly higher profit margin and a small adjustment to the assumed future P/E as the main reasons for maintaining their view.Narrative Update • Apr 07
ILM1: Cannabis Partnership And CFO Transition Will Support Future Upside Potential
Analysts have reduced their price target for Medios by €1 to €26, reflecting updated views that incorporate slightly higher revenue expectations, more moderate profit margin assumptions, and a higher future P/E multiple. What's in the News Medios plans a CFO change, with Stefan Bauerreis appointed to take over as Chief Financial Officer from April 15, 2026, following the end of Falk Neukirch’s term on April 30, 2026 (company announcement).Narrative Update • Mar 23
ILM1: Cannabis Partnership And Financing Progress Will Support Future Upside Potential
Analysts are keeping their €27.00 price target for Medios unchanged, citing only small adjustments to their revenue growth, profit margin, and future P/E assumptions as the main reasons for this steady view. What's in the News Chief Financial Officer Falk Neukirch will leave Medios when his current term ends in April 2026 at his own request, after playing a key role in repositioning and expanding the group under CEO Thomas Meier.Narrative Update • Mar 09
ILM1: Cannabis Partnership Expansion Will Support Future Upside Potential
Analysts have maintained their €27.00 price target for Medios, citing slightly higher modeled revenue growth, modestly stronger profit margins, and a marginally lower future P/E assumption as the key drivers in their refreshed view. What's in the News Medios is expanding its product portfolio by entering the medicinal cannabis market through a partnership with Dutch producer Bedrocan International B.V., which supplies pharmaceutical grade cannabis from an EU GMP certified Danish facility (Key Developments).Narrative Update • Feb 23
ILM1: Cannabis Partnership Expansion Will Support Future Share Upside
Analysts have kept their Medios price target steady at €27.00, with minor model tweaks to revenue growth, profit margin and future P/E assumptions supporting an unchanged view. What's in the News Medios is expanding its product portfolio by entering the medicinal cannabis market through a partnership with Bedrocan International, a manufacturer of pharmaceutical grade cannabis (Key Developments).Narrative Update • Feb 08
ILM1: Cannabis Expansion And Confirmed 2025 Outlook Will Support Future Share Upside
Analysts now maintain their price target for Medios at €27.00, citing minor adjustments to assumptions for the discount rate, revenue growth, profit margin and future P/E that ultimately balance each other out in their updated models. What's in the News Medios is expanding its product portfolio into medicinal cannabis by partnering with Bedrocan International B.V., a manufacturer of pharmaceutical grade cannabis, with a focus on the German market and a gradual rollout across additional EU countries over the next two years (Key Developments).Narrative Update • Jan 24
ILM1: Cannabis Expansion And New Leadership Will Support Future Share Upside
Analysts have kept their price target on Medios steady at €27.00, with only minor model tweaks around long run revenue growth, profit margin and future P/E assumptions supporting this unchanged view. What's in the News Medios is expanding its product portfolio into medicinal cannabis through a partnership with Bedrocan International, securing exclusive distribution rights for Bedrocan products in Germany, Spain, Belgium, Italy and Austria, with initial supply from an EU GMP certified Danish facility and additional production sites planned from 1 January 2027 (Key Developments).Narrative Update • Jan 10
ILM1: Index Inclusion And New Leadership Will Support Future Share Upside
Analysts have kept their fair value estimate for Medios steady at €27.00. The latest price target update reflects adjusted expectations for slightly lower revenue growth, a marginally higher profit margin outlook, and a small change in the assumed future P/E.Narrative Update • Dec 13
ILM1: Index Inclusion Will Increase Visibility And Support Future Share Upside
Analysts have lowered their price target on Medios from €32.00 to €27.00, citing tempered revenue growth expectations and a higher discount rate. These factors more than offset slightly improved profit margin assumptions, despite a lower projected future P/E multiple.Analysis Article • Oct 08
Market Still Lacking Some Conviction On Medios AG (ETR:ILM1)
With a median price-to-earnings (or "P/E") ratio of close to 18x in Germany, you could be forgiven for feeling...Analysis Article • Aug 15
Is Medios (ETR:ILM1) Using Too Much Debt?
XTRA:ILM1 1 Year Share Price vs Fair Value Explore Medios's Fair Values from the Community and select yours The...Analysis Article • May 21
Shareholders Will Probably Hold Off On Increasing Medios AG's (ETR:ILM1) CEO Compensation For The Time Being
Key Insights Medios' Annual General Meeting to take place on 27th of May Salary of €366.0k is part of CEO Matthias...Analysis Article • Apr 02
There May Be Some Bright Spots In Medios' (ETR:ILM1) Earnings
Soft earnings didn't appear to concern Medios AG's ( ETR:ILM1 ) shareholders over the last week. Our analysis suggests...Analysis Article • Mar 28
Medios AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
The annual results for Medios AG ( ETR:ILM1 ) were released last week, making it a good time to revisit its...
New Narrative • Mar 14
Expansion Into Advanced Therapies Will Diversify Revenue Streams And Strengthen Market Position
Integration of Ceban drives synergies, enhancing revenue and net margins through cross-selling and economies of scale.Analysis Article • Feb 18
Is It Time To Consider Buying Medios AG (ETR:ILM1)?
Medios AG ( ETR:ILM1 ), is not the largest company out there, but it saw a double-digit share price rise of over 10% in...Analysis Article • May 21
Medios (ETR:ILM1) Is Posting Promising Earnings But The Good News Doesn’t Stop There
The market seemed underwhelmed by last week's earnings announcement from Medios AG ( ETR:ILM1 ) despite the healthy...Analysis Article • Aug 19
Here's Why Medios (ETR:ILM1) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Mar 02
Is Medios AG (ETR:ILM1) Trading At A 39% Discount?
Key Insights Medios' estimated fair value is €32.44 based on 2 Stage Free Cash Flow to Equity Medios' €19.82 share...Analysis Article • Nov 27
Is Medios (ETR:ILM1) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Oct 21
Is It Too Late To Consider Buying Medios AG (ETR:ILM1)?
Medios AG ( ETR:ILM1 ), is not the largest company out there, but it saw a double-digit share price rise of over 10% in...Analysis Article • Aug 12
Here's Why Medios (ETR:ILM1) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Jul 07
Is Now The Time To Look At Buying Medios AG (ETR:ILM1)?
Medios AG ( ETR:ILM1 ), might not be a large cap stock, but it saw a significant share price rise of over 20% in the...Analysis Article • Apr 28
Is Medios (ETR:ILM1) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Mar 07
Here's Why I Think Medios (ETR:ILM1) Is An Interesting Stock
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Feb 08
What Does Medios AG's (ETR:ILM1) Share Price Indicate?
While Medios AG ( ETR:ILM1 ) might not be the most widely known stock at the moment, it received a lot of attention...Analysis Article • Nov 29
Medios (ETR:ILM1) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Oct 02
Is There Now An Opportunity In Medios AG (ETR:ILM1)?
Medios AG ( ETR:ILM1 ), might not be a large cap stock, but it saw significant share price movement during recent...Analysis Article • Jun 18
Medios AG's (ETR:ILM1) Intrinsic Value Is Potentially 35% Above Its Share Price
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Medios AG ( ETR:ILM1...Analysis Article • May 25
What Is Medios AG's (ETR:ILM1) Share Price Doing?
Medios AG ( ETR:ILM1 ), might not be a large cap stock, but it received a lot of attention from a substantial price...Shareholder Returns
| ILM1 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -9.0% | 1.7% | 1.7% |
| 1Y | -15.0% | 7.6% | 4.1% |
Return vs Industry: ILM1 underperformed the German Healthcare industry which returned 6.3% over the past year.
Return vs Market: ILM1 underperformed the German Market which returned 3.2% over the past year.
Price Volatility
| ILM1 volatility | |
|---|---|
| ILM1 Average Weekly Movement | 5.7% |
| Healthcare Industry Average Movement | 5.6% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: ILM1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: ILM1's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 993 | Thomas Meier | www.medios.ag |
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies.
Medios AG Fundamentals Summary
| ILM1 fundamental statistics | |
|---|---|
| Market cap | €272.99m |
| Earnings (TTM) | €13.94m |
| Revenue (TTM) | €2.12b |
19.6x
P/E Ratio0.1x
P/S RatioIs ILM1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILM1 income statement (TTM) | |
|---|---|
| Revenue | €2.12b |
| Cost of Revenue | €1.92b |
| Gross Profit | €199.50m |
| Other Expenses | €185.55m |
| Earnings | €13.94m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 12, 2026
| Earnings per share (EPS) | 0.57 |
| Gross Margin | 9.40% |
| Net Profit Margin | 0.66% |
| Debt/Equity Ratio | 39.0% |
How did ILM1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/04 07:19 |
| End of Day Share Price | 2026/08/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medios AG is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Heider | Berenberg |
| Michael Kuhn | Deutsche Bank |
| Martin Comtesse | Jefferies LLC |